Kate DeVarney, EVP and CSO of Titan Pharmaceuticals (NASDAQ:TTNP), was elected to the board at the company’s annual meeting.
Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January 2007 and spearheaded the development of Probuphine, the first six-month implant approved in the U.S., Canada and Europe for the treatment of opioid use disorder in eligible patients.
Prior to joining Titan, she served as senior director at Corcept Therapeutics and as senior medical director for neurosciences within World Wide Human Health at Merck. Throughout her career, Dr. DeVarney’s research has focused primarily on addiction; neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease; mood and anxiety disorders; metabolic disorders; and obesity.
“Kate’s leadership of the clinical development and medical affairs team at Titan is greatly valued by all, and we welcome her as a board member and look forward to her future contributions to the growth of the company,” Titan executive chairman, Dr. Marc Rubin, said in a statement.
Dr. DeVarney replaces Dr. Rajinder Kumar, who retired from the Titan board in December.
